| 期 |
栏目 |
标题 |
文件 |
| 卷 30, 编号 1/2 (2023) |
Pediatria |
Adverse reactions in children to antimicrobials: limitations of the spontaneous reporting method and the possibilities of the global trigger method for drug-induced conditions |
|
| 卷 30, 编号 4/5 (2023) |
Original articles |
Pharmacogenetic factors of haloperidol’s safety in adolescents experiencing acute psychotic episodes |
|
| 卷 30, 编号 8 (2023) |
Pharmacological properties of drugs |
Expert Council Resolution “The place of quifenadine in the treatment of allergic diseases and the classification of antihistamines” |
|
| 卷 30, 编号 9/10 (2023) |
Cardiology |
The influence of genetic resistance to antiplatelet agents on clinical and laboratory parameters and outcomes in ST-segment elevation myocardial infarction |
|
| 卷 30, 编号 9/10 (2023) |
Pulmonology/ENT/ARVI |
Lipid peroxidation in the body of patients with tuberculosis |
|
| 卷 30, 编号 12 (2023) |
Original articles |
Consumption of oral anticoagulants in hospitals of the Russian Federation: analysis of the dynamics of procurement data |
|
| 卷 31, 编号 1 (2024) |
Cardiology |
On the possible relationship between the presence of polymorphic variants of CYP3A4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease |
|
| 卷 31, 编号 4 (2024) |
Cardiology |
Safety of direct oral anticoagulants in the treatment of atrial fibrillation in geriatric patients: focus on clinically relevant non-major bleeding |
|
| 卷 31, 编号 6 (2024) |
Pulmonology/ENT/ARVI |
Association between CES1, CYP3A genetic polymorphisms and remdesivir hepatotoxicity in patients with COVID-19 |
|
| 卷 31, 编号 9 (2024) |
Коморбидность |
Development of an algorithm for predicting the risk of cough development during enalapril therapy in patients with arterial hypertension |
|
